Newsstand Menu

CSHL Stories and Media archive for Tag: RNA therapeutics

Unusual drug target and drug generate exciting preclinical results in mouse models of metastatic breast cancer

12/22/2015

Researchers publish preclinical data suggesting the promise of a novel drug directed against a novel target n malignant mammary tumors. Read the story »

Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells

11/3/2012

Researchers find method to target the cancer cell's metabolic process to destroy it. Read the story »

CSHL-led team introduces new method to closely model diseases caused by splicing defects

8/15/2012

Researchers find novel method of making animal models for human genetic disease research. Read the story »

CSHL announces collaboration to speed development of new cancer therapies

6/13/2012

Short hairpin RNA collection applied to advanced mouse models aims to accelerate drug target validation. Read the story »

Antisense therapy delivers long-term correction of severe spinal muscular atrophy in mice

10/5/2011

Researchers report surprising results that suggest that spinal muscular atrophy might not exclusively affect the motor neurons in the spinal cord. Read the story »

Collaboration column: SMA therapeutics and potential drug target for schizophrenia

3/11/2011

CSHL's Adrian Krainer works on treatment for spinal muscular atrophy that reverses the disease's symptoms. Read the story »

New method powerfully boosts efficiency of RNA interference (RNAi) in shutting down genes

2/24/2011

CSHL-led team finds an accurate, scalable way to identify potent RNAi triggers for biological studies and for RNA therapeutics. Read the story »

CSHL researchers demonstrate efficacy of antisense therapy for spinal muscular atrophy

7/12/2010

Researchers look into the use of chemically-modified pieces of RNA called antisense oligonucleotides to treat SMA. Read the story »

Cold Spring Harbor Laboratory scientists devise potential approach to treat spinal muscular atrophy

4/4/2008

CSHL and Ionis Pharmaceuticals have induced cells to replenish the protein by activating an existing, slightly modified copy of the mutant gene. Read the story »

CSHL shows correcting RNA splicing may help treat spinal muscular atrophy

3/12/2007

PLoS Biology publishes "Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon" Read the story »

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.